INGN
Inogen, Inc.
INGN has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over INGN overall, supported by stronger fundamentals and stronger modeled upside.
INGN Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Under pressure | |
| Strong |
INGN's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
INGN PE Valuation
INGN has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
INGN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Decline | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect INGN's losses to shrink, with revenue declining.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over INGN on the outlook, with more favorable revenue expectations.
INGN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.31 | -$0.30 |
| Q2 2026 | -$0.90 | +$0.16 |
| Q1 2026 | -$0.91 | +$0.24 |
| Q4 2025 | -$0.86 | +$0.66 |
| Q3 2025 | -$1.01 | +$1.25 |
| Q2 2025 | -$1.06 | +$2.92 |
| Q1 2025 | -$1.15 | +$3.01 |
| Q4 2024 | -$1.52 | +$2.90 |
INGN is still losing money, but far less than before: $1.31 per share over the past year, against $5.75 at its worst in late 2023.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over INGN on earnings quality, reporting a profit while its opponent remains loss making.
INGN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $77.2M | -16% |
| Q2 2026 | $95.1M | +3% |
| Q1 2026 | $85.1M | +3.4% |
| Q4 2025 | $81.7M | +2% |
| Q3 2025 | $92.4M | +4% |
| Q2 2025 | $92.3M | +4% |
| Q1 2025 | $82.3M | +5.5% |
| Q4 2024 | $80.1M | +5.5% |
INGN's revenue fell from its 2022 peak and has held roughly level since: $77M last quarter, down 16% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -20% | -13 points |
| Q2 2026 | -5.4% | +1.3 points |
| Q1 2026 | -11% | -1.7 points |
| Q4 2025 | -11% | +2.8 points |
| Q3 2025 | -7.7% | +1.1 points |
| Q2 2025 | -6.6% | +1.3 points |
| Q1 2025 | -9.3% | +12 points |
| Q4 2024 | -14% | +24 points |
INGN's operating margin was −20% last quarter, down 12 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over INGN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over INGN on profitability, with a higher operating margin.
INGN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$4.8M | -397% |
| Q2 2026 | $2.2M | -39% |
| Q1 2026 | -$6.9M | +$10.2M |
| Q4 2025 | -$1.9M | +$1.4M |
| Q3 2025 | $1.6M | -70% |
| Q2 2025 | $3.7M | -45% |
| Q1 2025 | -$17.1M | -$11M |
| Q4 2024 | -$3.3M | +$1.2M |
INGN's free cash flow was −$11M over the past year, against −$15M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over INGN on cash generation, producing positive trailing cash flow while its opponent burns cash.
INGN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -2.2% | -584K shares |
| 1 year | -2.3% | -614K shares |
| 3 years | +14% | +3.2M shares |
| 5 years | +16% | +3.6M shares |
| Available history | +21% | +4.6M shares |
INGN has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.7M |
| Q2 2026 | $5.6M |
| Q1 2026 | $1.9M |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
INGN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2022 | -122.1x | Net Cash |
| Q1 2022 | -13.6x | Net Cash |
| Q4 2021 | -8.9x | Net Cash |
| Q3 2021 | -9.0x | Net Cash |
| Q2 2021 | -13.6x | Net Cash |
| Q1 2021 | -80.5x | Net Cash |
| Q4 2020 | -103.4x | Net Cash |
| Q3 2020 | -110.1x | Net Cash |
INGN has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
INGN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.4 | Neutral |
| Stochastic | 47.7 | Neutral |
INGN's weekly RSI is 43 (neutral) and its Stochastic is 48 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
INGN PE vs Healthcare Sector
| Metric | INGN | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
INGN has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
INGN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.17 | 8.9% below |
| 20 week MA | $6.02 | 6.6% below |
| 50 week MA | $6.28 | 11% below |
| 100 week MA | $7.07 | 21% below |
| 200 week MA | $8.28 | 32% below |
INGN is in a downtrend: it's below all five of its weekly moving averages, and 32% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over INGN on trend strength, trading above more of its moving averages.
INGN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $68.5 | $43.3 | -37% |
| 2021 | $43.3 | $32.7 | -25% |
| 2022 | $32.7 | $19.9 | -39% |
| 2023 | $19.9 | $5.49 | -72% |
| 2024 | $5.49 | $8.58 | +56% |
| 2025 | $8.58 | $6.80 | -21% |
| 2026 YTD | $6.80 | $5.62 | -17% |
INGN has finished lower in five of the last six years. It's down 17% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over INGN on returns for 2026, with the stronger performance.